Pharma major Novartis falls 10% after three drug trial setbacks

Live updates

1. 2d ago

   Novartis Faces Shareholder Pressure After Clinical Failures

   Pharmaceutical major Novartis faces mounting pressure after experimental treatments missed clinical targets, including a late-stage study for the rare muscle-wasting condition myotonic dystrophy type 1. The experimental therapy del-desiran failed to demonstrate a statistically significant improvement over placebo regarding its primary endpoint, video hand opening time. This latest setback follows a sequence of adverse pipeline developments. In response to the clinical failures, a major shareholder, Artisan Partners, demanded a board shake-up at the Swiss drugmaker.

   Why it matters

   The recent clinical setbacks raise serious questions regarding the long-term growth pipeline of Novartis. The failed late-stage trial centers on a condition that currently lacks approved treatments, heightening the commercial impact. And clinical failures involving pharmaceutical pipelines can trigger wider market reactions across the biotechnology sector.

   What is confirmed

   • Novartis suffered a setback when its experimental drug del-desiran failed a late-stage trial for myotonic dystrophy type 1.
   • The experimental treatment did not show a statistically significant improvement over a placebo on video hand opening time.
   • A major shareholder, Artisan Partners, called for a board shake-up at the Swiss drugmaker.

   Still unconfirmed

   • The trial setbacks are heading toward the worst day on record for Novartis shares.

   What to watch next

   • Formal responses from the Novartis board regarding the demanded leadership shake-up
   • Further updates on the commercial and clinical status of the twelve billion dollar Avidity acquisition portfolio
   Sources used for this update (5)

   1. www.cnbc.com — Europe News
   2. www.pharmexec.com — Artisan Partners’ Director Calls for Novartis Board Shake-Up
   3. finance.yahoo.com — Drug Trial Setbacks Raise Questions Over Novartis (NVS)’s Growth Pipeline
   4. medicaldialogues.in — Novartis Major Shareholder Calls for Board Shake-Up After Back-to-Back Drug Trial Setbacks
   5. www.insidermonkey.com — Novartis’ Failed Cholesterol Drug Trial Sends Ionis and Amgen Tumbling
   confidence 95%
2. 6d ago

   Novartis Plummets 10% After Three Drug Trial Setbacks

   Pharmaceutical major Novartis dropped 10 percent, heading toward its worst day on record, following a sequence of three pipeline and drug trial setbacks within a single week. The latest blow involves a dystrophy drug from the twelve billion dollar Avidity acquisition falling short in a Phase 3 rare muscle disease study. This third consecutive failure has triggered heavy share sell-offs across international markets as investors absorb the cumulative impact of these clinical developments.

   Why it matters

   The steep market reaction reflects deep concern over the commercial viability of a high-value corporate acquisition. Three separate clinical pipeline failures inside a single week put intense pressure on company leadership to reassure shareholders. Unresolved questions remain regarding how these clinical misses will impact the broader RNA drug portfolio and future revenue projections.

   What is confirmed

   • Pharma major Novartis fell 10% following three drug trial setbacks.
   • The company experienced its third setback of the week when an Avidity drug failed a Phase 3 dystrophy study.
   • The latest trial failure involves a rare muscle disease study for an RNA drug.

   What to watch next

   • Further statements from Novartis management regarding the Avidity acquisition and pipeline strategy.
   • Additional data releases or regulatory filings concerning the affected rare muscle disease treatments.
   Sources used for this update (5)

   1. CNBC — Pharma major Novartis plummets 10%, heading for worst day on record after three drug trial setbacks
   2. Reuters — Novartis shares sink on second pipeline setback this week
   3. Bloomberg.com — Novartis Sees Avidity Drug Fail in Third Setback in a Week
   4. BioSpace — Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
   5. BioPharma Dive — Novartis RNA drug falls short in rare muscle disease study
   confidence 100%